D. E. Shaw & Co., Inc. Cassava Sciences Inc Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $56,858 - $86,518	3,417 Added 26.01%	16,553 $275,000
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $283,606 - $366,231	13,136 New	13,136 $322,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $158,729 - $258,300	-4,869 Reduced 9.88%	44,400 $1.65 Million
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $448,030 - $1.45 Million	-10,721 Reduced 17.87%	49,269 $3.06 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $1.93 Million - $5.38 Million	59,990 New	59,990 $5.13 Million

201

13.9M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.